The objective of this study is to determine if, compared to placebo, zonisamide (400mg/day) is a safe and efficacious treatment for post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) in Veterans with PTSD and co-occurring AUD.
This is a randomized, double-blind, placebo-controlled study to examine the ability of 5-weeks treatment with zonisamide to reduce symptoms of PTSD and AUD. The study population will consist of 60 Veterans with combat-related PTSD and co-morbid AUD. Veterans will be randomized 1:1 to receive either zonisamide (up to 400 mg/day) or placebo daily for 35±4days, followed by a 14-day down-titration period with follow-up. Primary efficacy variables are scores on the CAPS-5, fear-potentiated startle (FPS) responses, and percent of heavy drinking days (%HDD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
Michael E. DeBakey Veterans Affairs Medical Center
Houston, Texas, United States
Change from baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity score
CAPS-5 is a 30-item questionnaire, corresponding to the DSM-5 diagnosis for PTSD. All symptoms are assessed on a five-point scale (0=Absent, 1=Mild/subthreshold, 2=Moderate/threshold, 3=Severe/markedly elevated, 4=Extreme/incapacitating). CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms, possible scores ranging from 0-80 with higher values indicating a worse symptom severity.
Time frame: Baseline to post-treatment (weeks 0, 3, 5, 7)
Percent change in fear-potentiated startle (FPS) responses from acquisition on day 1 to recall on day 35.
Time frame: Baseline to post-treatment (weeks 1, 5, 7)
Change from baseline in the percent of heavy drinking days (%HDD)
Timeline Follow-Back (TLFB) of self-report assessment of heavy drinking days over the course of the five-week study treatment.
Time frame: Baseline to post-treatment (weeks 0-7)
Severity and numbers of AEs
All safety analyses will be performed using the safety population (i.e., as treated) unless otherwise specified. Rates, severity and relatedness of adverse events including serious adverse events, study drug-related adverse events, and deaths will be evaluated.
Time frame: Baseline to post-treatment (weeks 0-7)
Treatment retention
Retention will be assessed as a comparison count of participants at baseline and post-treatment.
Time frame: Baseline to post-treatment (weeks 0-5)
Medication compliance
We will use self-report and pill count. Overall percentage of pills taken will be calculated and reported.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline to post-treatment (weeks 0-5)
Medication adherence
To assess medication adherence, urine samples collected at study visits will be tested for riboflavin, using a quantitative assessment of fluorescence. Results will be summarized over time for the active treatment study group.
Time frame: Baseline to post-treatment (weeks 0-5)
Blood pressure
Systolic and diastolic blood pressure results will be summarized over the time of the study.
Time frame: Baseline to post-treatment (weeks 0-7)
Heart rate
Heart beats per minute will be summarized over the time of the study.
Time frame: Baseline to post-treatment (weeks 0-7)
ECG abnormalities
Frequency of ECG Summary results (i.e. Normal, Abnormal but clinically insignificant, or Abnormal and clinically significant) will be summarized over the time of the study.
Time frame: Baseline to post-treatment (weeks 0-7)
Breath alcohol content (BAC)
BAC as measured by an alcohol breathalyzer test, lower percentages indicating less alcohol breath content.
Time frame: Baseline to post-treatment (weeks 0-7)
Subjective and psychometric effects of alcohol (e.g. mood, urge/craving)
Alcohol Urge Questionnaire (AUQ) scores will be calculated, with higher scores reflecting higher craving.
Time frame: Baseline to post-treatment (weeks 0-7)
Alcohol use measures
Drinks per day including days abstained from drinking will be evaluated.
Time frame: Baseline to post-treatment (weeks 1, 3, 7)
Presence and symptom assessments for PTSD
PTSD Checklist for DSM-5 (PCL-5) scores will be calculated, with higher scores reflecting higher severity.
Time frame: Baseline to post-treatment (weeks 0-7)
Change from baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) subscale scores: Criterion B (reexperiencing)
CAPS-5 is a 30-item questionnaire, corresponding to the DSM-5 diagnosis for PTSD. All symptoms are assessed on a five-point scale (0=Absent, 1=Mild/subthreshold, 2=Moderate/threshold, 3=Severe/markedly elevated, 4=Extreme/incapacitating). Criterion B is the sum of items 1-5 (scores range 0-20). A higher score indicates worse symptom severity.
Time frame: Baseline to post-treatment (Weeks 0, 3, 5, 7)
Change from baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) subscale scores: Criterion C (Avoidance)
CAPS-5 is a 30-item questionnaire, corresponding to the DSM-5 diagnosis for PTSD. All symptoms are assessed on a five-point scale (0=Absent, 1=Mild/subthreshold, 2=Moderate/threshold, 3=Severe/markedly elevated, 4=Extreme/incapacitating). Criterion C is the sum of items 6 and 7 (scores range 0-8). A higher score indicates worse symptom severity.
Time frame: Baseline to post-treatment (Weeks 0, 3, 5, 7)
Change from baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) subscale scores: Criterion D (negative alterations in cognitions and mood)
CAPS-5 is a 30-item questionnaire, corresponding to the DSM-5 diagnosis for PTSD. All symptoms are assessed on a five-point scale (0=Absent, 1=Mild/subthreshold, 2=Moderate/threshold, 3=Severe/markedly elevated, 4=Extreme/incapacitating). Criterion D is the sum of items 8-14 (scores range 0-28). A higher score indicates worse symptom severity.
Time frame: Baseline to post-treatment (Weeks 0, 3, 5, 7)
Change from baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) subscale scores: Criterion E (hyperarousal)
CAPS-5 is a 30-item questionnaire, corresponding to the DSM-5 diagnosis for PTSD. All symptoms are assessed on a five-point scale (0=Absent, 1=Mild/subthreshold, 2=Moderate/threshold, 3=Severe/markedly elevated, 4=Extreme/incapacitating). Criterion E is the sum of items 15-20 (scores range 0-24). A higher score indicates worse symptom severity.
Time frame: Baseline to post-treatment (Weeks 0, 3, 5, 7)